Author: Avalon Health Economics LLC

Avalon Health Economics will be attending ISPOR Vienna, October 29th-November 2nd
October 1, 2017 - 12:11 pm, by
John Schneider & Andrew Briggs will be teaching the Economics of Diagnostics Introduction Course on Sunday afternoon (1:00pm-5:00pm). Come say hi or sign up for the course! Let us know if you would like to schedule a time to meet in Vienna.
AHE Presents: Symposium on Emerging Trends in U.S. Health Economic Evaluation: A Closer Look at the Role of Cost Effectiveness in U.S. Market Access, Tuesday May 9th in Morristown, NJ
April 1, 2017 - 4:19 pm, by
Avalon Health Economics Presents: Symposium on Emerging Trends in U.S. Health Economic Evaluation: A Closer Look at the Role of Cost Effectiveness in U.S. Market Access Tuesday, May 9th at the Hyatt Regency in Morristown, NJ The past year has been a tumultuous time for US health economics, characterized by the confluence of at least six...
The Value of Biopharmaceutical Innovation in the U.S.
February 22, 2017 - 3:55 pm, by
There have been some negative reports recently regarding the pricing practices of some pharmaceutical companies. However, it is important to give at least equal consideration to the value derived from the intensive level of research and development undertaken by the biopharmaceutical industry in the U.S. The invention of new products and processes has been shown...
The Evolving Landscape of U.S. Payer Coverage Decisions: The Role of Health Economics and Outcomes Research
December 7, 2016 - 3:37 pm, by
Although there are a large number of public and private payers in the U.S., medical device and pharmaceutical manufacturers generally focus on two types of payers: (1) Medicare, which is administered by the Centers for Medicare and Medicaid Services (CMS) and covers individuals ages ≥ 65; and (2) private commercial payers (e.g., Blue Cross and...
Will an Unravelling of the Affordable Care Act Result in Meaningful Organizational Changes in U.S. Medical Care? Implications for Economic Evaluation of Drugs & Devices
December 6, 2016 - 3:34 pm, by
In recent years, there has been a shift in U.S. health care markets to a broader, population-based perspective when assessing the costs and benefits of medical innovation. Cost effectiveness analysis and budget impact analysis results can look quite different when viewed from the perspective of a health system or an accountable care organization, and can...
Medical Device Economics and the Health System Purchaser in the Era of Novel Payment Mechanisms
May 31, 2016 - 3:29 pm, by
Hospitals in the U.S. spend an estimated 40% of their annual budgets on supplies, medical devices and equipment alone.[1, 2] According to the American Hospital Association, in 2015 total expenditures by U.S. hospitals was $808 billion.[3] That implies that if the 40% supply and equipment estimate is correct, hospitals are spending more than $320 billion...
Analysis of Dental and Vision Plan Non-Covered Services and Materials Mandates and the Projected Role of H.R. 3323 in the Vision and Dental Markets
April 27, 2016 - 12:09 pm, by
Our research found that for doctors of optometry and dentists in both states, even after the enactment of laws barring NCS mandates, the vast majority of providers continued to offer normal discounts and receive payments from patients that were below their charged amounts. Thus, the laws had no effect on the providers—they continued billing their...
Value-Based Payment for Oncology Services
March 7, 2016 - 3:26 pm, by
Cancer care is a large part of overall health care expenditures. Of the approximately 18% of U.S. gross domestic product spent on healthcare, more than 5% is attributed to cancer treatments.[1] Considering the premature mortality associated with cancer, the humanistic and economic toll is enormous. Consequently, in recent years there has been increasing attention devoted...
Why Medical Device Companies Need to Develop Economic Evidence in the U.S.
January 14, 2016 - 3:24 pm, by
Although the U.S. lacks a centralized health technology evaluation agency, as many of the European countries maintain, in recent years there has been considerable pressure to control the rising costs of new biopharmaceuticals and medical devices.[1-5] After relatively slow growth in the 1960s, U.S. health care expenditures grew intensely in the decades between 1980 and...
Avalon CEO John Schneider presented at BMO Capital Markets’ “The Year Ahead in Healthcare: Products, Payment and Politics” on December 15, 2015
December 29, 2015 - 12:08 pm, by
Avalon CEO John Schneider, Ph.D. presented at BMO Capital Markets’ “The Year Ahead in Healthcare: Products, Payment and Politics” on December 15, 2015. The day-long symposium was focused on markets for life science products and featured presentations from industry leaders, including Boston Scientific, Medtronic, Abbott and Pfizer. Schneider delivered a lunchtime presentation on the medical...
Avalon Health Economics LLC